Allogene Therapeutics

📍 South San Francisco, United States👥 379 employees💰 Last funded Sep 2018
Biotechnology🌐 allogene.com
Website LinkedIn
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Allogene Therapeutics?
Allogene Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Allogene Therapeutics last raise funding?
The most recent investment in Allogene Therapeutics recorded on gritt.io was in September 2018.
What industry is Allogene Therapeutics in?
Allogene Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Allogene Therapeutics based?
Allogene Therapeutics is headquartered in South San Francisco, United States.